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1. Introduction
Systemic vasculitides are a heterogenous group of disorders characterized by destructive
inflammation and fibrinoid necrosis of the blood vessel wall, blood vessel occlusion and
ischemia of surrounding tissue. Typical clinical manifestations vary depending on the size of
the affected blood vessels, and include fever, weight loss, malaise, arthralgias and arthritis.
Vasculitides can be idiopathic, primary, secondary to another disease such as Systemic Lupus
Erythematosus (SLE) and Rheumatoid Artritis (RA), or associated with infections, such as
infective endocarditis, pharmaceutical drug use, such as propylthiouracil and hydralazine, or
other chemical exposures [1]. Vasculitis can be isolated to one organ or vessel and be relatively
insignificant clinically or can present as a systemic life-treatening illness involving several
organs and vessels [2].
ANCA- associated Systemic Vasculitis (AASV) is the most common primary systemic small-
vessel vasculitis that occurs in adults. AASV is a small-vessel vasculitis affecting arterioles,
venules, capillaries, and occasionally medium-sized arteries that commonly involves multiple
organ systems. Although infrequent, the incidence of AASV is increasing. AASV is also called
pauci-immune vasculitis, because no immunoglobulins or complement components are
detected in the vasculitic lesions.
AASV is associated with significant morbidity and mortality, with almost all patients requiring
aggressive immunosuppression. Without treatment, the mortality approaches 100% in 5 years
[3]. Based upon the clinical presentation and the predominant organ involvement, AASV cases
are classified as Wegener’s granulomatosis (WG), microscopic polyangiitis (MPA), Churg-
Strauss syndrome (CSS) and Renal Limited Vasculitis (RLV). ANCA are predominantly IgG
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antibodies that were first described in the 1980s by Davies et al. in patients with necrotizing
glomerulonephritis [4]. These antibodies are directed against antigenic components of
neutrophilic granules or lysosomes. Indirect immunofluorescence (IIF) of ethanol-fixed
neutrophils reveals cytoplasmic (cANCA) or perinuclear (pANCA) staining. cANCA staining
correlates with proteinase-3 (PR3) reactivity, while pANCA staining correlates with reactivity
towards myeloperoxidase (MPO) or other antigens.
PR3-ANCAs are mainly detected in patients with WG, whereas MPO-ANCAs are predomi‐
nantly detected in patients with MPA and CSS. These diseases exhibit similar pathological
focal necrotizing lesions, though WG and CSS also have granulomatous lesions [5].
Henoch-Schönlein purpura (HSP) is the most common systemic small-vessel vasculitis in
children [6]. HSP is a systemic vasculitis affecting small vessels and capillaries. HSP is
characterized by palpable purpura, edema, abdominal pain, joint pain and renal symptoms [7].
The prognosis is good as long as the patients have no renal symptoms. Renal symptoms vary
from intermittent hematuria and proteinuria to rapidly progressive glomerulonephritis.
In this chapter, we shall discuss the pathophysiology of the most common primary small vessel
vasculitis in adults, AASV, as well as the most common small vessel vasculitis in children,
HSP.
2. History
Purpura was the first manifestation of vasculitis in vessels smaller than arteries. In 1808, Willan
clearly distinguished purpura caused by infections from non-infectious purpura [8]. Over the
next century, Henoch and his teacher, Schönlein, described a broad spectrum of signs and
symptoms that were associated with purpura, and with small vessel vasculitis, including
arthritis, peripheral neuropathy, abdominal pain, pulmonary hemorrhage, epistaxis, iritis, and
nephritis [9].
In 1866, Kussmaul and Maier described a patient with general weakness caused by vasculitic
neuropathy accompanied by tachycardia, abdominal pain, and the appearance of cutaneous
nodules over the trunk. The patient’s muscle paralysis progressed quickly causing death. At
autopsy, visible nodules were present along the medium-sized arteries of the patient [10].
Kussmaul and Maier named this disease “periarteritis nodosa” because they observed
inflammation in the perivascular sheaths and outer layers of the arterial walls and nodular
thickening of the vessels. However, the name was later changed to “polyarteritis nodosa”
because of the widespread involvement of vessels and the fact that it affects the entire thickness
of the vessel wall [1].
A disorder of necrotizing vasculitis, granulomatous lesions of the entire respiratory tract, and
glomerulonephritis was first described in 1897 by Peter McBride [11]. In 1931, Heinz Klinger
described the pathological anatomical picture of this disease in two patients who died of
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systemic vasculitis [12]. In 1936, Friedrich Wegener, a German pathologist, described three
patients with necrotizing granuloma and later interpreted the pathological and clinical
findings to represent a distinctive disease entity in 1939 [13]. Goodman and Churg in 1954
wrote a detailed description of the disease known as “Wegener´s granulomatosis” (WG)
presenting definite criteria: necrotizing granulomata of the respiratory tract, generalized
vasculitis and necrotizing glomerulonephritis [14]. DeRemee and colleages in 1976 proposed
the ELK classification (E= upper respiratory tract including paranasal sinuses; L= lung; K=
kidney), allowing them to understand and manage cases that did not fit the strict criteria of
Goodman and Churg [15]. In the early 1970s, Fauci and Wolff introduced treatment with
cyclophosphamide and corticosteroids for WG, which resulted in a nearly complete and long-
lasting remission of the disease [16]. In addition, DeRemee published in 1985 a report on the
benefits of using cotrimoxazole (trimethoprim/ sulfamethoxazole) in WG with local disease
[17]. In the same year, a major breakthrough was made by Van der Woude et al who reported
autoantibodies sensitive and specific for the disease. These autoantibodies reacted with the
cytoplasm of ethanol-fixed neutrophils, and monocytes and were called Anti-neutrophil
Cytoplasmic Autoantibodies (ANCA) [18].
3. Classification
There are 20 recognized primary forms of vasculitis, which are classified according to the size
of the affected blood vessels. The large vessel vasculitides, giant cell (temporal) arteritis and
Takayasu arteritis, are caused by a granulomatous inflammation of the aorta and its major
branches. In the case of giant cell arteritis, there is a particular predeliction for the extracranial
branches of the carotid artery, often with involvement of the temporal artery and frequent
association with polymyalgia rheumatica. The age of the patient is helpful in distinguishing
between the two conditions, because giant cell arteritis is rare in patients under the age of 50
and Takayasu’s disease is more common in younger patients [19].
Classical polyarteritis nodosa affects medium-sized vessels and therefore should not involve
glomerulonephritis or vasculitis in arterioles, capillaries or venules. Kawasaki’s disease is a
medium-sized vessel vasculitis that frequently involves the coronary arteries, is associated
with the mucocutaneous lymph node syndrome and is most common in children [2].
Small vessel vasculitides include the immune-complex associated vasculitis of Henoch-
Shoenlein pupura and essential cryoglobulinemic vasculitis. Henoch-Schönlein pupura has
predominantly IgA immune complex deposition and involves the skin, gut and glomeruli with
arthritis and arthralgia, while essential cryoglobulinemic vasculitis is caused by the deposition
of cryoglobulins predominantly in the small vessels of the skin and glomeruli and is frequently
associated with Hepatitis C infection. Another small vessel vasculitis category is cutaneous
leucocytoclastic vasculitis, which is confined only to the skin, has no systemic involvement
and has a better prognosis than vasculitides with systemic involvement [2].
Examples of different types of vasculitis are depicted in Table 1.
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Dominant vessel involved Primary Secondary
Large arteries Giant cell arteritis
Takayasu’s arteritis
Aortitis associated with RA
Infection (eg. Syphilis)
Medium arteries Classical PAN
Kawasaki disease
Infection (eg. Hepatitis B)
Small vessels and medium arteries Wegener’s granulomatosis*
Churg-Strauss syndrome*
Microscopic polyangiitis*
Vasculitis 2 to RA, SLE, Sjögren’s syndrome
Drugs
Infection (e.g. HIV)
Small vessels (leukocytoclastic) Henoch-Schönlein purpura
Essential mixed cryoglobulinaemia
Cutaneous leukocytoclastic vasculitis
Drugs**
Infection (e.g. Hepatitis B, C)
(*) Diseases most commonly associated with ANCA, pausi-immune crescentic glomerulonepghritis and which are most
responsive to immunosuppression with cyclophosphamide. (**) e.g. sulphonamides, penicillins, thiazide diuretics, and
many others. PAN= Polyarteritis Nodosa. RA= Rheumatoid Arthritis. SLE= Systemic Lupus Erythematosus.
Table 1. Classification of systemic vasculitis.
ANCA-associated systemic vasculitis (AASV) are a group of diseases classified as small vessel
vasculitides that are associated with anti-neutrophil cytoplasmic antibodies. AASV include
microscopic polyangiitis, Wegener´s granulomatosis, Churg-Struass syndrome and renal
limited vasculitis. Together they are responsible for 5-6% of cases presenting with renal failure.
They are characterized histologically by necrotizing vasculitis preferentially affecting small
blood vessels and often associated with pauci-immune necrotizing crescentic glomeruloneph‐
ritis. Serologically, these diseases present autoantibodies directed against constituents of
neutrophil granules [20].
In1990, three independent groups showed that azurophilic granule enzyme proteinase 3 was
the target autoantigen recognized by ANCA (PR3-ANCA) [21,22,23]. Together with proteinase
3, another granule protein, myeloperoxidase (MPO) was also identified as a target autoantigen
of ANCA (MPO-ANCA) [24]. The discovery of ANCA has been critical to understanding the
pathogenesis of the disease, as well as providing a valuable diagnostic tool. The American
College of Rheumatology published criteria for classifying vasculitides in 1990, leading to
improved categorization of patients for clinical trials [25]. However, these criteria were not
adequate for diagnosing patients with ANCA-associated vasculitides. An individual patient
could simultaneously meet the criteria for WG, Churg Strauss Syndrome (CSS), Polyarteritis
Nodosa (PAN), hypersensitivity vasculitis and Henoch-Schönlein pupura. In 1994 the Chapel
Hill Consensus conference (CHCC) adopted standardized names and definitions of vasculi‐
tides, based on the size of the affected blood vessels [26].
Recently a group of physicians from multiple medical disciplines met at the European
Medicines Agency (EMEA) in London in September 2004 and January 2006 and developed a
stepwise algorithm for classifying AASV and PAN for epidemiological studies. Their aim was
to develop a consensus approach for applying CHCC definitions and ACR criteria to AASV
and PAN, in order to facilitate comparison between epidemiological data for different
vasculitides [27].
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Without treatment, patients with AASV have a very poor prognosis with a median survival
time of 5 months [28]. Current treatment regimens based on cyclophosphamide and cortico‐
steroids have dramatically improved the prognosis for these patients and increased the median
survival time to 21.7 years [29]. Although this regimen achieves long-lasting remission and
prolonged survival of patients with AASV, it has its drawbacks; the worst being life-threat‐
ening infections early in the course of the disease and risk of malignancy in late stages of the
disease [30,31]. Furthermore, the disease has a high relapse rate in spite of heavy immuno‐
suppression. Improved understanding of the mechanisms underlying AASV may help in the
search for better treatment modalities for this serious and devastating illness.
4. Pathophysiology of ANCA-Associated Systemic Vasculitis (AASV)
The pathophysiology of AASV remains largely unknown. Clinical and laboratory evidence
suggest a multifactorial origin. Although the association between ANCA and pauci-immune
small vessel vasculitides has been established, the exact role of ANCA in the pathogenesis of
AASV is yet not fully elucidated. It is not known whether ANCA play a direct role in disease
manifestations, or whether the antibodies are secondary markers of the disease process.
Available data suggest that neutrophils, B- and T- lymphocytes play a key role in the patho‐
physiology of AASV.
4.1. Pathogenic B-cell response and production of ANCA
B-cells are the direct precursors of antibody producing plasma cells. B-cells also produce auto-
antibodies and cytokines (Interleukin IL-6, Tumor Necrosis Factor alpha-TNFα, IL-10), act as
antigen presenting cells, and differentiate into long lasting memory B-cells. Csernak et al. have
shown that in WG patients, ANCA are produced following B-cell activation [32]. A polyclonal
B-cell lymphoid infiltrate in the endonasal granulomatous lesion included PR3-ANCA-
producing cells with copy number increase in three VH genes. The granulomatous lesions in
WG consist of clusters of PR3 surrounded by an infiltrate consisting of maturing B-cells,
antigen-presenting cells (APCs) and Th1-type CD4+CD28− T cells. This suggests that endo‐
nasal B-cell maturation is antigen-driven, and that B-cells generate ANCA via contact with
PR3 or an antigenic microbial epitope [33].
B-cells recognize soluble antigens via specific B-cell receptors (BCR) and co-receptor CD19 that
augments BCR downstream signaling. CD19 dysregulation has been reported in patients with
AASV. Culton et al. showed that CD19 expression is 20% lower in naive B-cells from patients
with AASV than from normal controls [34]. In contrast, the memory B-cells from some patients
with AASV express more CD19 than normal controls. This subset of B-cells shows evidence
of antigenic selection, suggesting that in AASV, mechanisms of self-tolerance may be lost
leading to production of auto-reactive B-cells [34]. Experiments in transgenic mice indicate
that defective B-cell regulation, specifically in pathways responsible for deletion (central and
peripheral) of auto-reactive B-cells, may also play a role in generating autoantibodies in AASV
[35]. Interestingly, expression of B-cell activating factor of the TNF family (BAFF) is increased
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in patients with WG [36]. It is postulated that BAFF may drive B-cell expansion, which then
leads to ANCA production. B-cell depletion via rituximab in patients with AASV decreases
ANCA levels and induces disease remission [37,38]. Conversely, clinical relapse correlates
with increase levels of B cells [39]. These data support the conclusion that B cells play a central
role in ANCA production and that ANCA play a significant role in the pathogenesis of AASV.
4.2. Pathogenic T-response, tissue damage, and granuloma formation
Under normal conditions, naïve T-cells are activated during an immune response to an antigen
stimulus. Antigen-specific T-cells then differentiate into memory T-cells, while effector-T cells
undergo apoptosis. Paucity of immunoglobulins in the vasculitic lesions, predominance of
IgG1 and IgG4 subclasses of IgG, and the presence of granulomatous lesions indicate that T-
cell-mediated immune responses play a role in the pathogenesis of AASV [40]. This is consis‐
tent with the fact that T cell-based treatment strategies produce clinically-relevant remission
in AASV patients [41,42].
In patients with active WG, higher proportion of activated T-cells and higher concentration of
soluble T cell activation markers (including soluble IL-2 receptor or CD30) are reported to
correlate with disease activity [43]. High levels of activation markers also correlate with
ANCA-positivity, which suggests persistent T cell activation, likely secondary to a persistent
antigenic trigger, as an underlying pathogenic factor. This is consistent with reports of
persistent expansion of CD4+ effector memory T-cells (Tem) combined with a decrease in naïve
T-cells in patients with AASV [44,45]. A polarization of Th1 and Th2 response has also been
reported in AASV. In particular, a Th2-type response is predominant in patients with active
generalized WG or CSS, while a Th1 response is dominant in patients with localized WG or
MPA, indicating that aberrant T cell response plays a role in the disease process [46,47]. CCR5
is also expressed on T-cells in early, localized WG, which might also favor recruitment of Th1-
type cytokine secreting cells into inflammatory lesions in localized WG [48]. Conversion from
Th1 to Th2 type response could underlie progression from localized to generalized WG. This
shift could reflect B-cell expansion and T-cell-dependent PR3-ANCA production, secondary
to interaction between neutrophils and auto-reactive T- and B-cells in inflammatory lesions,
Figure 1.
The granulomas in AASV resemble a germinal centre, with a cluster of primed neutrophils
surrounded by dendritic cells, T- and B-cells. CD4+ T cells are likely to play an important
role in the granulomatous response in AASV. The decrease in CD4+CD28-- Tem subset of T-
cells during active disease, in patients with WG, indicates an increased migration of these
cells to sites of inflammation [44]. In an experimental model of autoimmune, anti-MPO-asso‐
ciated glomerulonephritis, it was noted that mice depleted of CD4+ T cells, at the time of ad‐
ministration of anti-mouse anti-GBM antibodies, developed significantly less crescent
formation and cell response, compared to controls [49]. In patients with ANCA-associated
glomerulonephritis, Tem cells are the predominant T-cell subtype in the glomerular infil‐
trate [50]. Together, these observations suggest that a cell mediated immune response con‐
tributes to the pathogenesis of renal lesions. Indeed, CD4+ Tem cells from WG patients lack
NKG2A (inhibitory receptor) and demonstrate increased expression of NKG2D, which is a
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member of the killer immunoglobulin-like receptor family [51]. A significant increase in the
proportion of IL-17 producing CD4+ T cells (Th17 cells) in in vitro stimulated peripheral
blood cells from WG patients has also been reported [52]. IL-17 induces secretion of neutro‐
phil-attracting chemokines, and release of pro-inflammatory cytokines (IL-1β, TNF-α) capa‐
ble of increasing expression of PR3 on the surface of neutrophils. Patients with ANCA-
positive WG are reported to have more PR3-specific Th17 cells than ANCA-negative WG
patients and healthy controls [52]. It is, therefore, likely that a Th1 response plays an impor‐
tant role in antibody production and granuloma formation in AASV.
Figure 1. Pathophysiology of AASV. The stimulation of neutrophils by TNF-α or IL-1β (priming), e.g. during a preceding
infection, leads to the translocation of the ANCA-antigens, PR3 and MPO, from the cytoplasmic granules (specific
granules and secretory vesicels) to the cell surface, where they are accessible for ANCA, which leads to a further activa‐
tion of the cell. ANCA-induced neutrophil activation initiates production of ROS, neutrophil degranulation with re‐
lease of inflammatory cytokines and granule contents (e.g., PR3 and HLE) from azurophilic granules, leading to
endothelial cell detachment and lysis. Furthermore, neutrophil activation leads to leukocyte adhesion (via ICAM-1,
VCAM-1) and transmigration through endothelium (via PECAM-1), and release of ROS and proteases into tissues. Su‐
perantigen (e.g., Staphylococcal exotoxins) or PR3 presented to the T-cells directly or via dendritic cells, are capable of
stimulating the proliferation of T-cells, leading to granuloma formation and finally to maturation of PR3-specific au‐
toreactive B-cells, culminating in ANCA production. ROS= Reactive oxygen species. PR3= Proteinase 3, MPO= Myelo‐
peroxidase, HLE= Human Leukocyte elastase, ICAM= Intercellular adhesion molecule-1, VCAM-1=Vascular cell
adhesion molecule-1, PECAM-1= Platelet endothelial cell adhesion molecule-1, TCR= T-cell receptor, MHC-II= Major
Histocompatibility complex-II, TNF-α=Tumor necrosis factor-alpha, IL-1β=Interleukin-1 Beta.
History, Classification and Pathophysiology of Small Vessel Vasculitis
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4.3. Monocyte activation and production of pro-inflammatory cytokines
Wickman et al compared monocytes and cytokine profiles in patients with acute anti-PR3
vasculitis and normal controls; monocytes from patients were reported to have a reduced
capacity to produce oxygen radicals [53]. Ohlsson et al., from our group, reported a positive
correlation between circulating levels of IL-8 and monocyte IL-8 mRNA in patients with AASV,
suggesting prolonged immune activation [54]. Pathological analysis of renal tissue from
patients with AASV revealed the presence of monocytes in the glomerular crescents and
granulomas [55]. In-vitro studies demonstrated that ANCA are capable of stimulating
monocytes, leading to release of cytokines including IL-8, MCP-1, TNF-, IL-1, IL-6 and
thromboxane A2 [56,57]. On the other hand, membrane PR3 expression on monocytes does
not correlate with disease activity. There are many possible explanations for the presence of
activated monocytes in glomerular crescents. For example, it is possible that monocytes are
activated by direct physical interaction with components of glomerular lesions once they reach
site of lesion; alternatively, dysfunctional apoptosis may stimulate monocyte activation [58].
4.4. Endothelial cell activation and enhanced expression of adhesion molecules
Endothelial damage, neutrophil invasion and necrosis are histopathological features of AASV
[59]. Activated endothelial cells express high levels of adhesion molecules. Increased circulat‐
ing levels of endothelial proteins (thrombomodulin, vWF), and adhesion molecules (soluble
intercellular adhesion molecule (sICAM)-1 and the soluble endothelial cell-leukocyte adhesion
molecule (sELAM)-1) have been reported in vasculitis [60]. Woywodt et al. reported the
presence of significant number of circulating endothelial cells and necrotic endothelial cell
fragments in patients of active AASV [61]. A significant proportion of the circulating endo‐
thelial cells (EC) stain positive for tissue factor (TF), which links proinflammatory mechanisms
with thrombosis [61]. Interestingly, TF expression can be induced in ECs by the release of PR3
and elastase from neutrophils; this may be mediated via PR3 receptors on the endothelial cell
surface [62]. Endothelial cell necrosis, and release of TF, may play a role in development of
vasculitic lesions. The mechanism of endothelial cell necrosis is not yet fully elucidated.
Although anti-endothelial cell antibodies have been detected in AASV, their significance in
this regard is not clear [63]. ANCA antigens, PR3 and MPO, can bind to endothelial cells via
endothelial cell receptors [64,65]. ANCA can bind to endothelial cell bound antigens, leading
to EC activation. It is possible that ANCA-induced neutrophil activation induces release of
cytotoxic enzymes that damage endothelial cells. In AASV patients with renal involvement,
the levels of circulating angiopoietin-2 (Ang-2) correlate with the increased number of
circulating ECs. In-vitro studies suggeset that the endothelial-specific angiopoietin (Ang)-Tie
ligand-receptor system regulates endothelial cell detachment. By analogy, Ang-2 might
regulate endothelial cell detachment in AASV [66].
4.5. Environmental factors
Clinical and epidemiological evidence demonstrate that environmental factors, including
silica, asbestos, drugs (anti-thyroid medications), and various infections (bacterial endocardi‐
tis, hepatitis C visrus), correlate with circulating ANCA and development of AASV [67,68].
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Beaudreuil et al showed that exposure to silica is associated with a nearly seven-fold increased
risk of being ANCA-positive [69]. ANCA, both PR3 and MPO, are detected in sera of patients
with protracted infections; however, in most infections, ANCA are directed against a wide
repertoire of antigens and tend to be dual [70]. Stegeman et al. described an association between
nasal S. aureus and relapses of PR3-AAV [71]. Chronic infections may prime neutrophils,
which can be further activated by PR3-ANCA, leading to vasculitis. It is also possible that some
exogenous non-self proteins (i.e., bacterial, viral, fungal) mimic auto-antigens, which generates
ANCA and an ANCA response. For example, PR3-ANCA has been detected in sera of patients
with bacterial endocarditis [72]. Long standing exposure of the immune system to specific
antigens, may set the stage for development of ANCA and subsequent AASV. Many theories
have been made in line of this thought, including anti-complementary PR3 antibody theory
[73] and Anti-LAMP (Lysosomal associated membrane protein) anatibody theory [74], which
are out of the scope of this study.
4.6. Genetic predisposition
In general, autoimmune diseases display familial inheritance, suggesting that affected
individuals carry genetic variation that contributes to disease susceptibility. Case reports show
clusters of WG in siblings and close relatives, and specific HLA associations (DR1-DQw1) in
AASV patients also suggest the existence of genetic susceptibility loci [75,76,77]. In patients
with WG, neutrophils with positive expression of membrane-PR3 (mPR3+) are more abundant
than in healthy controls, leading to a skewed bimodal distribution of mPR3 towards a high
mPR3+ phenotype in WG [78]. This phenomenon may be genetically determined, because the
proportion of mPR3+neutrophils is a stable phenotype in the same individual over prolonged
periods of time, it also runs in families and is similar between twins [79]. Furtherore, patients
with WG carry a polymorphism that disrupts a putative transcription factor binding site in
the PR3 promoter region [80]. This polymorphism may lead to increased expression of PR3
and explain the high mPR3+ phenotype. Additional polymorphisms involving CTLA-4
(affecting T cell activation), alpha-1 antitrypsin level (protease inhibitor of PR3), and other
genes/proteins have been reported in AASV patients [81,82,83,84].
5. Are ANCA pathogenic?
The subject of pathogenicity of ANCA is controversial. ANCA are absent in some patients with
small vessel vasculitis, while MPO-ANCA are detected in patients with rheumatoid arthritis
and other disorders [85]. Also, a paucity of immune complexes at sites of pathological lesions
argues against a direct role for ANCA. However, animal models of small vessel vasculitis
provide convincing evidence that ANCA are pathogenic in AASV. Xiao et al demonstrated
that Rag2-/- mice, which are completely deficient in T- and B-lymphocytes with antigen
receptors, developed a severe necrotizing glomerulonephritis and small vessel vasculitis when
they were injected with anti-MPO splenocytes, while mice that received anti-BSA or normal
splenocytes remained disease-free. Similarly, Rag2-/- and WT B6-mice injected with anti-MPO
IgG developed focal glomerular necrosis and crescent formation, clearly indicating that the
History, Classification and Pathophysiology of Small Vessel Vasculitis
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antibodies were pathogenic [86]. Neumann et al demonstrated excessive immune deposits in
the early stages of life of SCG/Kinjoh mice (that spontaneously develop small vessel vasculitis
and p-ANCA), and suggested that immune complex deposition leads to an inflammatory state,
which when amplified by ANCA, likely lead to severe vasculitis [87]. In renal biopsies from
AASV patients with renal involvement, Bajema et al showed that PR3, MPO, elastase and
lactoferrin localized within or around fibrinoid necrotic lesions, and the lesions contained high
levels of PR3 and elastase, which were also enriched inside the lesions [88]. Schlieben et al
described a case of pulmonary renal syndrome in a newborn who received MPO-ANCA via
passive transfer from the mother, supporting the idea that ANCA are pathogenic [89]. Animal
models have not been developed to text the pathogenicity of PR3-ANCA, because human and
murine PR3 share a low level of homology. However, an animal model of vasculitis and severe
segmental and necrotizing glomerulonephritis, similar to WG, was recently developed in non-
obese diabetic-severe combined immune deficiency (NOD-SCID) mice. In this model, spleno‐
cytes were isolated from NOD mice immunized with recombinant mouse PR3 and transferred
into NOD-SCID mice, who developed disease pathology. These findings suggest that PR3-
ANCA may play a direct role in PR3-ANCA-associated renal disease; however, in this model,
a specific genetic background and autoimmune predisposition for kidney pathology are pre-
requisites for disease manifestation [90].
5.1. Role of neutrophil apoptosis in AASV
Increased neutrophil apoptosis has been observed in AASV. Pathological specimens from
patients of WG show clear presence of apoptotic and necrotic neutrophils [91,92]. Leucocytes,
with degraded nuclear material, undergoing disintegration and apoptotic cells have been
observed in tissue specimens from ANCA-positive renal vasculitis [93]. Histologically, AASV
is characterized by leukocytoclasis, with infiltration and accumulation of unscavenged
apoptotic and necrotic neutrophils in tissues around blood vessels, and fibrinoid necrosis of
the blood vessel walls [94]. E/M studies of the leukocytoclastic lesions, in patients with
leukocytoclastic vasculitis, have suggested that there may be a defect in the clearance of
apoptotic neutrophils. The minority of neutrophils in this study showed typical apoptotic
changes of the condensed and marginated nuclei, while the majority showed intact nuclei with
disintegrated cytoplasmic organelles and plasma membranes [95]. Apoptotic neutrophils may,
in fact, be a source of immunologically exposed neutrophil antigens that promote the produc‐
tion of ANCAs. It has been speculated that the development of ANCA-positive vasculitis is a
three-step pathological process. The first step involves an exogenous stimulus that increases
neutrophil and macrophage apoptosis. An example is exposure to an inhaled substance like
silica, which is known to induce apoptosis in human peripheral blood lymphocytes and to also
induce Fas-ligand expression in lung macrophages (in vitro and in vivo), promoting Fas-
dependent macrophage apoptosis in a murine model of silicosis [96,97]. Similarly, other
postulated etiological agents for AASV (propylthiouracil, Streptococcus Pneumoniae) have also
been shown to induce/accelerate apoptosis [98,99]. There is also pathological evidence of
leucocytes with degraded nuclear material undergoing disintegration in tissues and apoptotic
cells have been observed in AASV. Therefore, it seems logical to suggest that defective
clearance/increased exposure to apoptotic neutrophils may be the initiating factor for ANCA
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production and development of AASV (step two). Finally, environmental and genetic factors
can also contribute to disease expression [100].
There are also experimental data that support this developmental model. There is evidence
that in an inflammatory environment, autoantigens (nuclear/cytosolic) are presented by the
opsonized cells, likely resulting in autoantibody formation. Kettritz et al used high doses of
TNF-α to prime neutrophils, and demonstrated that caspase 3 dependent early neutrophil
apoptosis was accompanied by increased surface expression of PR3 and MPO. In addition,
these early apoptotic neutrophils showed a down-regulation of respiratory burst in response
to ANCA [101].
Interestingly, Patry et al showed that injection of syngenic apoptotic neutrophils, but not
freshly isolated neutrophils, into Brown Norway rats resulted in development of P-ANCA,
with the majority being specific for elastase, again indicating that apoptotic neutrophils may
boost an autoimmune response [102]. In another study, intraperitoneal infusion of live or
apoptotic human neutrophils (but not formaline fixed or lysed neutrophils) into C57BL/6J mice
resulted in development of ANCA specific for lactoferrin or myeloperoxidase. A second
intravenous infusion of apoptotic neutrophils resulted in the development of PR3-specific
ANCA. Again no vasculitic lesions were found in those mice developing ANCA [103].
As already known from general molecular biology knowledge, neutrophils migrating to
inflamed sites undergo spontaneous apoptosis leading to their clearance without damage to
the surrounding tissue. Macrophages in the blood recognize, among other surface membrane
signals, the externalized Phosphatidyl Serine (PS) on the apoptotic neutrophils leading to their
safe clearance. However, neutrophils that are not cleared in this manner progress to secondary
necrosis, a process that triggers the release of pro-inflammatory cytokines. It appears that
ANCAs dysregulate the process of neutrophil apoptosis. In an in vitro study conducted by
Harper et al., ANCAs accelerated apoptosis of TNF--primed neutrophils by a mechanism
dependent on NADPH oxidase and the generation of ROS. This was accompanied by uncou‐
pling of the nuclear and cytoplasmic changes from the surface membrane changes. That is,
while apoptosis progressed more rapidly, there was no corresponding change in the rate of
externalization of PS following activation of neutrophils by ANCAs. This dysregulation
created a ‘reduced window of opportunity’ for phagocyte clearance by macrophages, leading
to a more pro-inflammatory environment [104]. It must be noted here that ANCAs were unable
to accelerate apoptosis in unprimed neutrophils. Additionally, although there was increased
expression of PR3 and MPO as apoptosis progressed, ANCAs were unable to activate these
neutrophils. In fact, there was a time-dependent decrease in ROS generation as these neutro‐
phils aged [104]. ANCA accelerates neutrophil apoptosis, in primed neutrophils, via genera‐
tion of ROS that act as amplifying factors for apoptosis. ROS are critical since neutrophils
isolated from patients with chronic granulomatous disease (having a defect in ROS production)
do not show accelerated apoptosis after ANCA activation [104]. The same authors, in a later
study, as well as another independent group showed that ANCA binding to apoptotic
neutrophils enhanced phagocytosis by human monocyte-derived macrophages, but at the
same time they increased the secretion of pro-inflammatory cytokines like IL-1, IL-8 and TNF-
α [105,106]. IL-1 and IL-8 are capable of retarding apoptosis and are powerful chemo-attrac‐
tants. The pro-inflammatory neutrophil clearance will result in further cell recruitment and
perpetuation of inflammation. The autoimmune response may be promoted by aberrant
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phagocytosis of apoptotic neutrophils by dendritic cells. In a recent study it has been shown
that anti-PR3 antibody can also penetrate into human neutrophils (in vitro) and lead to
enhancement of the apoptotic process [107].
Understanding the pathogenesis of neutrophil apoptosis and clearance in AASV can help to
rationalize existing therapies and indicate new approaches to therapy [108].
5.2. The role of netting Neutrophils (NETs)
A novel form of PMN death named “NETosis”, characterized by the active release of chro‐
matin, has been described recently [109]. Neutrophil extracellular traps (NETs) are extrusions
of plasma membrane and nuclear material, containing granule components and histones.
These structures bind gram-positive and negative bacteria, as well as fungi. In vitro, NETs
have been shown to bind and kill extracellular microorganisms; in vivo, they have been
documented in conditions, including appendicitis, sepsis, pre-eclampsia and experimental
models of shigellosis [110]. The changes leading to NET formation follow a specific pattern,
which is initiated by the loss of nuclear segregation into eu- and heterochromatin. Once the
chromatin and granular components are mixed, NETs are released from the cell after cyto‐
plasmic membrane rupture by a process distinct from necrosis or apoptosis, termed NETosis.
NADPH oxidase plays a role in this process, via generation of ROS, which act as signaling
molecules. Fuchs et al demonstrated that NET formation is a part of active cell death, and that
NETs are released when the activated neutrophils dies [111].
Kessenbrock et al. demonstrated that ANCA-stimulated neutrophils release NETs, which
contain PR3 and MPO in addition to chromatin and LL37 (an antimicrobial peptide with
capabilities of activating dendritic cells) [112]. In-vivo presence of NETs was shown in tissues
(kidney biopsies from patients with small vessel vasculitis), with maximal concentration in
areas showing neutrophilic infiltration, which suggests that NET formation occurs predomi‐
nantly during active disease [112]. In patients of AASV, increased levels of circulating
nucleosomes has been reported [113]. It is likely that these may, in fact, be derived from and
reflect NET formation in AASV. In short, NETs may incite production of ANCA, via presen‐
tation of antigen-chromatin complexes to the immune system, or ANCA may incite production
of NETs, which then could aggravate the immune response, leading to perpetuation of the
auto-immune response, Figure 2.
5.3. Recent updates
Experiments performed by our group, have shown that the plasma levels of mature PR3 as
well as pro-PR3 are elevated in AASV [114,115,116]. It was also observed that mPR3+ neutro‐
phils are more abundant in AASV compared to healthy donors, which agrees with previous
studies suggesting that a high percentage of mPR3+cells may be a risk factor for vasculitis
[78,115]. Circulating neutrophils and monocytes from patients with AASV display upregulat‐
ed transcription of the PR3 gene [117]. It is likely that aberrant PR3/mPR3 expression may
reflect, or be a marker of a specific functional defect in neutrophils. A possible origin of high
plasma levels of PR3 is shedding of membrane PR3.
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A significant recent finding is that mPR3 and CD177 are co-expressed on the same subset of
circulating neutrophils in healthy subjects as well as in AASV patients [118,119]. Our group
has demonstrated that the mPR3+/CD177+neutrophil subpopulation was larger in AASV
patients as compared to healthy controls, which suggests a distinct pathophysiological
neutrophil phenotype in AASV [116]. Interestingly, higher CD177–mRNA, but not PR3–
mRNA was found to correlate with a higher proportion of mPR3+/CD177+cells, suggesting
that overproduction of CD177 could lead to an increase in the proportion of mPR3+/
CD177+neutrophils [116].
It is likely that these two subpopulations have distinct functions, which may have a direct
bearing on pathophysiological processes. Membrane CD177 helps neutrophils adhere to the
endothelium, while m-PR3 helps this positive subpopulation to migrate through the endothe‐
Figure 2. Pathophysiological model of neutrophil extracellular traps (NETs) in ANCAassociated vasculitis. ANCA can
induce TNF-α-primed neutrophils to produce NETs. The deposition of NETs may activate plasmacytoid dendritic cells
that produce large amounts of interferon-α driving the autoimmune response. In this context, NETs may activate au‐
toreactive B cells to the production of ANCA, which results in a vicious circle of NET production that maintains the
delivery of antigen–chromatin complexes to the immune system. Moreover, NETs may also stick to the endothelium
and cause endothelial damage.
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lium and interstitial tissues. It may be inferred that the mPR3+/CD177+ cells possess greater
killing capabilities, including higher NET and ROS production, than the mPR3–/CD177– sub-
population. In simplistic terms, the mPR3+/CD177+ neutrophils may be the designated
“fighting” neutrophils, designed to migrate from blood into tissues and promote pro-inflam‐
matory, microbicidal functions, while mPR3-negative neutrophils are destined to stay in the
intra-vascular compartment, and function as anti-inflammatory cells, until they are needed for
resolution of inflammation to produce anti-inflammatory mediators or to phagocytose tissue
debris and other dead neutrophils at the site of inflammation.
Our group is the first to demonstrate a lower rate of spontaneous apoptosis and longer in
vitro survival in neutrophils from AASV patients in remission as compared to neutrophils from
healthy blood donors [120].
Contrary to our results, Harper et al. showed that neutrophils from AASV patients, especially
those with active disease, have an accelerated rate of apoptosis [106].
6. Pathophysiology of Henoch-Schönlein Purpura (HSP)
The etiology of HSP as well as its pathogenesis are largely unknown.
6.1. Genetic factors
Familial clustering of HSP has been described and suggests a genetic background to the disease
[121,122]. In several countries and ethnic groups different HLA types have been associated
with susceptibility for HSP [123,124]. The different HLA type associations may explain
differences in manifestations between different ethnic groups, but, so far, no conclusions could
be drawn from these studies to explain the pathogenesis of HSP. Positivity for HLAB35 was
found to increase the risk for the development of HSP [125].
A polymorphism in the angiotensinogen gene (M235T) may confer risk for the development
of Henoch-Schönlein Nephritis [126,127].
Polymorphisms in the gene for angiotensin 1-converting enzyme (ACE) may be involved in
the pathogenesis of HSP or HSN, although data are conflicting. The insertion (I)/deletion (D)
genotype of a polymorphism in ACE may confer susceptibility to HSP [126,127]. The DD
polymorphism was related to persistent proteinuria in patients with HSP in one study [128],
whereas in another study no correlation was found between the prognosis of HSP and the ACE
genotype [129].
Variations in the complement C4 protein gene may confer susceptibility to the development
of HSP. C4 null isotypes have been described to be prevalent in a significantly higher propor‐
tion of patients with HSP and HSN than controls [130,131,132]. A partial or complete deficiency
of C4 could be related to impaired clearance of immune complexes and thus play a role in the
pathogenesis of HSP [133]. Complement deficiency is, however, uncommon and transient in
patients with HSP [134].
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Investigations addressing polymorphisms in genes encoding for proinflammatory cytokines
(TNF-α, IL-1b, IL-8, TGF-β and VEGF) have so far not revealed any predisposing factors for
HSP [135,136].
Familial mediterranean fever (FMF) is an autoinflammatory disease caused by a mutation in
the MEFV gene, which in 7 % of cases is associated with HSP [137]. There is a high prevalence
of children with MEFV mutations among HSP patients in countries with relative abundance
of FMF [138,139]. The implication this association has on the general pathogenesis of HSP is,
if at all, unclear.
6.2. Infectious and non-infectious agents
HSP is usually preceded by infections, in up to 95 % of cases localized in the upper respiratory
tract, and appears in clusters in families [140,141,142]. The incidence of HSP is highest during
early childhood and shows distinct seasonal variations with a peak during autumn and winter
[6]. Both early childhood and the autumn-winter season are periods with frequent infections.
Thus, clinical observations suggest an important role of infections in the etiology and patho‐
genesis of HSP.
Several studies have shown a circumstantial relation of infections with group A streptococci
and the development of HSP [143,144,145]. Others found serological evidence for an associa‐
tion with infections with other bacteria such as Bartonella henselae or viruses such as parvo‐
virus B19 and hepatitis C virus [146,147,148].
Non-infectious agents have been found to be associated with the development of HSP
especially in adults. These include certain drugs such as angiotensin-converting enzyme
inhibitors, angiotensin II-receptor antagonists, antibiotics, and non-steroidal anti-inflamma‐
tory drugs as well as insect bites, vaccinations or food allergies [149].
6.3. IgA1 in HSP
IgA deposits in HSP are composed of immune-complexes mainly consisting of IgA1 [150].
Serum samples from HSN patients were found to have elevated levels of underglycosylated
polymeric IgA1 compared to controls [151]. However, in children with HSP without renal
involvement the levels were not higher than those of controls [152]. Underglycosylated
polymeric IgA1 has been found to exhibit an inflammatory and proliferative effect on mesan‐
gial cells (see IgA1 in IgAN). Taken together, underglycosylated polymeric IgA1 seems to be
involved in the development of HSN, but its role in the pathogenesis of HSP per se remains
unclear.
6.4. Mediators of inflammation
The acute phase of systemic vasculitis is generally characterized by vascular leukocytic
infiltration and activation of innate immunity. Elevated levels of inflammatory cytokines are
usually detectable in the serum and affected tissues in these diseases.
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IL-6, TNF-α, tumor necrosis factor-like weak inducer of apoptosis (TWEAK), IL-8, TGF-β, and
VEGF have been found to be up-regulated during the acute stage of HSP [153,154].
Tissue samples of affected skin areas from patients with HSP show epidermal staining with
IL-6 [155]. Serum levels of IL-6 were significantly higher in patients with HSP during the acute
phase of disease than in controls and also higher in patients with HSN than HSP without renal
affection [153]. IL-6 displays a wide variety of pro-inflammatory properties and promotes the
secretion of IgA [153,156].
IL-6 displays, besides its various pro-inflammatory effects, even anti-inflammatory effects by
inhibiting TNF-α and IL-1 and activating IL-1ra as well as IL-10 [157].
TNF-α is produced by macrophages and T cells in affected skin areas during HSP. Serum levels
of TNF-α were higher in patients with HSN than HSP without renal engagement [153].
It stimulates the presentation of adhesion molecules and receptors on leukocytes and endo‐
thelial cells thereby directing inflammatory events. Furthermore, endothelial cells stimulated
with TNF-α were shown to bind IgA with higher affinity [155]. These findings suggest, that
TNF-α could be involved in the accumulation of granulocytes and endothelial sequestration
of IgA as seen in affected tissues in HSP [153].
TWEAK, a member of the TNF superfamily, which binds to specific receptors on endothelial
cells, is involved in the regulation of cell growth, angiogenesis, apoptosis, and inflammation.
In vitro evidence suggests that TWEAK may induce cytokine production by human micro‐
vascular endothelial cells via up-regulation of the production of IL-8 and CCL-5 leading to a
leucocyte migration into affected vessels [158,159] which are common aspects of the HSP
lesion.
Sera and IgA from patients with HSP induce the secretion of IL-8 from endothelial cells invitro
[160,161].
IL-8 is a potent chemoattractant for polymorphonuclear neutrophilic granulocytes (PMNs).
Levels of leukotriene B4, also a potent chemo-attractant and activator of PMNs, are elevated
both in serum and urine in patients with HSN compared to those with HSP.
Furthermore, the levels of leukotriene A4, which counter-balance the effects of leukotriene B4
and inhibit the synthesis of proinflammatory cytokines (e.g. IL-6, IL-8, TNF- α), are decreased
in patients with HSN [162].
The role of VEGF in HSP is not clear-cut. Serum levels of VEGF were significantly higher during
the acute phase of HSP than during remission. However tissue staining for VEGF showed more
intense staining for VEGF in the epidermis and vascular bed during the resolution phase than
during the acute phase of HSP [163]. High serum levels of VEGF could influence endothelial
permeability, which may enhance capillary leakage and facilitate the extravasation and
perivascular deposition of immune complexes. The increased tissue staining during the
resolution phase, on the other hand, suggests a possible function of VEGF in the resolution of
vascular damage.
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T helper cells (Th) are a sub-population of lymphocytes, which have an important role in
adaptive immune responses. Dependent on the surrounding cytokine environment naïve
Th-cells differentiate into subtypes with different functions [164]. In patients with HSP an
elevated number of Th2 and Th17 with increased synthesis of IL-5 and IL-13 have been
found together with increased serum levels of IL-4, IL-6, and IL-17A [165]. The differentia‐
tion  towards  Th2  is  stimulated  by  exposure  to  IL-4  and  towards  Th17  by  TGF-β  com‐
bined with IL-6. By secreting IL-4, Th2 exhibit a stimulatory effect on B cells and promote
the  generation  of  plasma cells.  Further  secretion  of  IL-5  or  IL-13  from Th2  leads  to  an
antibody switch in plasma cells towards the generation of IgA or IgE, respectively. Th17
secrete IL17, which in turn stimulates the expression of pro-inflammatory cytokines such
as IL-1,  IL-6,  and cell  adhesion factors and promotes leukocyte migration to the sites of
inflammation. Th17 has been implicated in the pathogenesis of autoimmune diseases [164].
An imbalance  of  Th with  Th2  and TH17 predominance,  as  seen  in  HSP,  could  explain
elevated serum levels of IgA and IgE, the expression of pro-inflammatory cytokines and
leukocyte infiltrations into affected tissues seen in HSP [166,167].
If the pieces of this puzzle are put together potential origins of cardinal symptoms of
HSP emerge. Neutrophilic infiltration of the perivascular region may be mediated by TNF-α,
TWEAK, IL-8, chemo-attractant leukotrienes, VEGF and/or Th17 and the extravasation and
deposition of IgA by IL-6, TNF-α, VEGF, and Th2. The development of HSN could be related
to the prevalence of underglycosylated polymeric IgA1, the effect of IL-6, TNF-α, and a
disturbed balance between chemo-attractant and counteracting leukotrienes.
The contact system, which induces liberation of bradykinin or other vasoactive kinins from
high-molecular kininogen, has been found to be activated in HSP, which could contribute
to the development of clinical  features such as inflammation,  vasodilatation,  edema and
pain [168].
Increased reactive oxygen species, lipid and protein oxidation, and nitric oxide level detectable
during the acute phase of HSP are believed to reflect secondary events and vascular damage
[169,170,171].
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